- Published on
Urology – Prostate Cancer: Locally Advanced Disease (Clinical T3–T4)
Definition, Pathophysiology, Risk Factors, Diagnostic Evaluation, Multimodal Treatment, and Prognosis
1. Definition and Clinical Overview
Locally advanced prostate cancer refers to prostate malignancy that extends beyond the prostate gland or invades adjacent anatomical structures.
The principal clinical stages are:
- cT3: Tumour extends beyond the prostate capsule or involves the seminal vesicles.
- cT4: Tumour is fixed or invades adjacent structures other than the seminal vesicles.
Locally advanced disease may be accompanied by regional lymph node involvement, but lymph node status must be recorded separately.
Main Clinical Categories
- cT3N0M0.
- cT4N0M0.
- cT3–T4N1M0.
Clinical Importance
Compared with organ-confined prostate cancer, locally advanced disease is associated with:
- Greater tumour burden.
- Increased likelihood of lymph node involvement.
- Greater risk of biochemical recurrence.
- Increased probability of distant metastasis.
- Higher prostate cancer-specific mortality.
Key Clinical Principle: Locally Advanced Prostate Cancer Frequently Requires Multimodal Treatment Because Surgery, Radiotherapy, Or Hormonal Therapy Alone May Be Insufficient For Durable Disease Control.
2. Clinical T3 Prostate Cancer
Definition
Cancer extending beyond the prostate gland.
Clinical findings may be identified through examination, while MRI provides additional information about the local extent.
T3 Subclassification
T3a – Extraprostatic Extension
Tumour extends through the prostatic capsule.
Extension may be unilateral or bilateral.
T3b – Seminal Vesicle Invasion
Tumour invades one or both seminal vesicles.
Clinical Importance
Seminal Vesicle Invasion Represents A More Advanced Local Tumour Pattern Than Extraprostatic Extension Alone.
3. Clinical T4 Prostate Cancer
Definition
Cancer that is fixed or invades adjacent structures beyond the seminal vesicles.
Important Structures
- External urethral sphincter.
- Rectum.
- Levator muscles.
- Pelvic wall.
Historical Source
The original chapter also describes bladder neck involvement as a T4 pathological feature.
Important Staging Qualification
Under contemporary pathological staging, microscopic bladder neck invasion is classified as pT3a, rather than automatically as pT4.
Stage assignment should distinguish microscopic bladder neck involvement from extensive macroscopic invasion or fixation.
Clinical Importance
T4 Disease Represents Extensive Local Invasion And Generally Requires Particularly Careful Multidisciplinary Treatment Planning.
4. Clinical Versus Pathological Stage
Clinical Stage
Based on pretreatment evaluation.
The EAU clinical T classification uses digital rectal examination findings, while MRI findings are reported separately for additional local staging information.
Pathological Stage
Determined by examination of surgically removed tissue.
Important Pathological Findings
- Extraprostatic extension.
- Seminal vesicle invasion.
- Surgical margin status.
- Lymph node metastases.
Clinical Importance
Clinical T3 Disease Does Not Always Correspond To Pathological T3 Disease Because Clinical Staging Can Both Overestimate And Underestimate Tumour Extent.
5. Epidemiology
Historical Incidence
The source describes a decline in locally advanced prostate cancer presentation during the PSA screening era.
1989–1990
Approximately 10–15% of prostate cancer presentations.
2001–2003
Approximately 1–5%.
Clinical Interpretation
Earlier detection contributed to a greater proportion of cancers being diagnosed while clinically localized.
Important Qualification
These percentages represent historical populations and should not be interpreted as current global incidence estimates.
6. Risk Factors
The probability of locally advanced disease increases with adverse tumour characteristics.
Principal Predictors
- Higher PSA.
- Higher Gleason score.
- Higher ISUP Grade Group.
- Greater tumour volume on biopsy.
- More extensive positive biopsy involvement.
Clinical Importance
A High PSA Combined With High-Grade Histology And Extensive Biopsy Involvement Strongly Raises Concern For Extraprostatic Disease.
7. Age and Other Associated Factors
Increasing Age
The source reports a greater likelihood of high-risk prostate cancer presentation among men aged 75 years or older.
Historical Population Associations
The source also describes associations involving:
- African American men.
- Diabetes mellitus.
Important Qualification
These were historical observational associations. Disease severity is influenced by biological risk, healthcare access, screening, and other factors.
Such characteristics should not independently determine cancer stage or treatment.
8. Genetics
The historical chapter notes ongoing research into molecular markers that distinguish organ-confined from locally advanced prostate cancer.
Contemporary Genetic Considerations
Relevant genes include:
- BRCA2.
- BRCA1.
- ATM.
- CHEK2.
- HOXB13.
- Selected mismatch-repair genes.
Clinical Significance
Inherited or tumour-acquired molecular abnormalities may influence:
- Cancer aggressiveness.
- Hereditary risk assessment.
- Treatment selection in advanced disease.
Important Principle
Genetic Testing Supplements Clinical Risk Assessment But Does Not Replace PSA, Grade Group, Imaging, Or Histopathological Staging.
9. Pathophysiology
Basic Mechanism
Locally advanced prostate cancer develops when malignant cells acquire the ability to penetrate normal anatomical barriers.
Important Biological Processes
- Loss of normal cellular adhesion.
- Extracellular matrix degradation.
- Tissue invasion.
- Altered growth signaling.
- Angiogenesis.
- Lymphovascular invasion.
Anatomical Progression
- Cancer develops within the prostate.
- Tumour grows beyond its original glandular structures.
- Extraprostatic extension develops.
- Seminal vesicles or adjacent structures may become involved.
- Regional or distant spread may subsequently occur.
Clinical Importance
Higher-Grade Prostate Adenocarcinoma Has A Greater Tendency Toward Extraprostatic Extension Than Low-Grade Cancer.
10. Histological Grade and Local Extension
Historical Comparison
Gleason 7–10
More commonly associated with extraprostatic disease than:
Gleason 6.
Modern Classification
- Grade Group 1: Gleason 3 + 3.
- Grade Group 2: Gleason 3 + 4.
- Grade Group 3: Gleason 4 + 3.
- Grade Group 4: Gleason 8.
- Grade Group 5: Gleason 9–10.
Clinical Importance
Grade Groups 4–5 are particularly associated with aggressive disease and greater progression risk.
11. Associated Clinical Conditions
Locally invasive prostate cancer may cause symptoms through obstruction or direct invasion.
Important Manifestations
- Hematuria.
- Weak urinary stream.
- Straining.
- Urinary retention.
- Irritative lower urinary tract symptoms.
- Pelvic pain.
- Changes in bowel habits.
Important Qualification
Some patients with locally advanced cancer remain relatively asymptomatic.
12. Prevention and Chemoprevention
The original chapter discusses several proposed preventive interventions.
Five-Alpha-Reductase Inhibitors
- Finasteride.
- Dutasteride.
Historical prevention studies demonstrated reduced prostate cancer detection rates.
However, these agents are not routinely recommended solely to prevent clinically significant prostate cancer.
Vitamin Supplements
The source specifically identifies no established benefit from:
- Vitamin E.
- Selenium.
- Vitamin C.
Other Proposed Agents
- Statins.
- Green tea.
- Lycopene.
Clinical Importance
There Is Insufficient Evidence To Recommend These Medications Or Supplements Specifically To Prevent Locally Advanced Prostate Cancer.
13. Diagnostic Evaluation
Main Objectives
- Confirm prostate adenocarcinoma.
- Determine tumour grade.
- Estimate local tumour extension.
- Assess seminal vesicle involvement.
- Evaluate regional lymph nodes.
- Exclude distant metastases.
- Assess suitability for curative treatment.
14. Clinical History
Family History
Ask about:
- Prostate cancer in first-degree relatives.
- Early-onset prostate cancer.
- Relevant hereditary cancer syndromes.
Lower Urinary Tract Symptoms
Assess:
- Weak urinary stream.
- Hesitancy.
- Urinary frequency.
- Urgency.
- Nocturia.
- Retention.
Other Symptoms
- Hematuria.
- Pelvic pain.
- Altered bowel habits.
- Bone pain.
- Weight loss.
Clinical Importance
New Bone Pain Or Systemic Symptoms Should Raise Concern For Metastatic Disease Rather Than Purely Locally Advanced Cancer.
15. Digital Rectal Examination
DRE.
Important Findings
- Prostatic nodularity.
- Induration.
- Unilateral or bilateral abnormalities.
- Loss of normal anatomical boundaries.
- Prostatic fixation.
- Extension into surrounding tissues.
Clinical Importance
A Fixed Prostate Or Palpable Invasion Of Adjacent Structures Raises Concern For Clinical T4 Disease.
Important Limitation
DRE alone may not accurately determine the full extent of the tumour.
16. Serum PSA
Clinical Role
PSA is a major component of prostate cancer risk assessment and staging.
Historical Positive Predictive Values
The source reports:
PSA 4–10 ng/mL
Approximately 12–32%.
PSA greater than 10 ng/mL
Approximately 60–80%.
Important Qualification
These are historical cancer-detection probabilities from particular clinical populations, not probabilities of locally advanced disease.
Clinical Importance
Higher PSA levels generally raise concern for greater tumour burden and more advanced disease, but PSA alone cannot establish tumour stage.
17. Factors Influencing PSA
PSA may be altered by:
- Prostate volume.
- Benign prostatic hyperplasia.
- Prostatitis.
- Urinary infection.
- Recent urinary retention.
- Relevant instrumentation.
- Five-alpha-reductase inhibitors.
Historical Laboratory Variation
The source reports variability of approximately:
20–25%.
Important Qualification
Analytical and biological PSA variability differ across assays and circumstances.
Unexpected results should be interpreted using repeated measurements when appropriate.
18. PSA Density
Definition
Serum PSA divided by prostate volume.
Formula
PSA Density = PSA / Prostate Volume.
Historical Thresholds
Greater Than 0.15 ng/mL/cm³
Associated with increased suspicion for prostate cancer.
Greater Than 0.35 ng/mL/cm³
Associated with a reported 66% risk of extraprostatic extension in a historical cohort.
Important Qualification
These figures are historical and should not be used as stand-alone contemporary staging thresholds.
19. PSA Velocity
Definition
The rate of PSA change over time.
Historical Criterion
Increase greater than 0.75 ng/mL/year.
Historical Assessment Method
At least three PSA measurements over approximately 18 months.
Contemporary Qualification
PSA velocity is not recommended as the sole basis for diagnosing cancer or estimating local stage.
Clinical Importance
PSA Kinetics May Contribute To Clinical Risk Assessment But Must Be Interpreted Alongside Grade Group, MRI, And Other Findings.
20. Percentage Free PSA
Historical Finding
Free PSA below 10%.
Associated with a reported prostate cancer probability of approximately:
56%.
Important Qualification
The probability depends on the total PSA and population studied.
Free PSA is mainly relevant to selected diagnostic decisions rather than accurate local T staging.
21. PCA3 Urine Test
Definition
A urinary molecular biomarker based on prostate cancer antigen 3 expression.
Historical Method
Urine collection following DRE.
Historical Performance
- Sensitivity: 48%.
- Specificity: 79%.
Clinical Role
Previously investigated to help decide whether repeat prostate biopsy was appropriate.
Important Qualification
PCA3 is not a routine staging investigation for locally advanced prostate cancer.
22. Transrectal Ultrasound
TRUS.
Historical Role
- Evaluate the prostate.
- Guide systematic needle biopsy.
- Assess suspicious local abnormalities.
Historical Accuracy for Extracapsular Extension
- Sensitivity: 23–66%.
- Specificity: 46–86%.
- Positive predictive value: 50–62%.
Clinical Importance
Conventional TRUS Has Limited Reliability For Detecting Extraprostatic Extension.
It should not be relied on as the sole local staging investigation.
23. Multiparametric MRI
Contemporary Role
MRI is an important investigation for local tumour assessment.
Main Applications
- Detect extraprostatic extension.
- Evaluate seminal vesicle invasion.
- Assess neurovascular bundle involvement.
- Identify adjacent structure invasion.
- Guide targeted biopsy.
- Assist radiation or surgical planning.
Historical Source
The chapter describes MRI as useful for differentiating T2 from T3 disease.
Clinical Importance
MRI Provides Important Information About Local Tumour Extension And Is More Useful Than Conventional TRUS For Many Local Staging Questions.
24. MRI Limitations
MRI cannot reliably identify every instance of microscopic extraprostatic extension.
Potential Difficulties
- Small-volume extension.
- Postbiopsy hemorrhage.
- Inflammatory abnormalities.
- Limited lesion conspicuity.
Clinical Importance
A negative MRI does not guarantee organ-confined disease.
25. Computed Tomography
CT.
Historical Indications
The original source recommends considering CT staging with:
- PSA greater than 20 ng/mL.
- Gleason score 8 or higher.
Contemporary Clinical Role
CT remains useful when evaluating:
- Pelvic and abdominal lymphadenopathy.
- Advanced anatomical abnormalities.
- Upper urinary tract dilatation.
- Other structural complications.
Important Limitation
CT may miss small-volume nodal metastases.
26. Bone Scintigraphy
Historical Threshold
PSA at least 20 ng/mL.
Clinical Purpose
Evaluate possible skeletal metastases.
Important Qualification
Bone scan use should depend on the full clinical risk and available imaging.
The PSA threshold in the historical source is not a universal rule.
27. PSMA PET/CT
Contemporary Role
PSMA PET/CT is a preferred staging modality for high-risk localized and locally advanced prostate cancer when available.
Important Applications
- Detect pelvic lymph node metastases.
- Identify distant lymph node disease.
- Identify bone metastases.
- Detect other distant metastatic lesions.
Clinical Importance
PSMA PET/CT Provides More Accurate Metastatic Staging Than Conventional CT And Bone Scintigraphy In Many Patients With High-Risk Prostate Cancer.
Important Qualification
Very small nodal metastases may remain undetected.
More sensitive staging can change a patient's apparent stage, and treatment recommendations must consider the imaging method used in the supporting clinical trials.
28. Historical ProstaScint Imaging
The source describes possible use of ProstaScint in locally advanced prostate cancer.
Contemporary Qualification
ProstaScint has largely been superseded by modern PSMA PET imaging.
It is not a preferred routine staging modality.
29. Prostate Biopsy
Clinical Role
Histological confirmation is generally necessary before definitive treatment.
Historical Method
TRUS-guided prostate biopsy.
Contemporary Approach
- MRI-directed sampling where appropriate.
- Targeted and perilesional cores.
- Systematic sampling when indicated.
- Transperineal approach preferred in European practice.
Clinical Importance
The Biopsy Must Establish Histology And Grade Group To Support Accurate Treatment Selection.
30. Seminal Vesicle or Targeted Additional Biopsy
The historical source describes biopsy of the capsule or seminal vesicles to demonstrate T3 disease.
Clinical Importance
Targeted sampling may be useful in selected situations when histological confirmation of suspicious extension would change management.
Important Qualification
Routine seminal vesicle biopsy is not required for every suspected locally advanced prostate cancer.
31. Histopathological Findings
Main Parameters
- Prostate adenocarcinoma.
- Gleason score.
- ISUP Grade Group.
- Tumour volume.
- Percentage of positive biopsy cores.
- Perineural invasion.
- Other adverse histological patterns.
Clinical Importance
High-Grade Histology And Extensive Biopsy Involvement Are Important Predictors Of Advanced Disease And Future Recurrence.
32. Differential Diagnosis
Elevated PSA
Possible causes include:
- BPH.
- Acute prostatitis.
- Chronic prostatitis.
- Urinary tract infection.
- Prostatic or urethral instrumentation.
Suspicious Imaging Findings
May represent:
- Prostate cancer.
- Prostatitis.
- Prostatic infarction.
- Other benign or malignant abnormalities.
Important Principle
No Single PSA Measurement, Examination Finding, Or Imaging Investigation Can Perfectly Predict Pathological Prostate Cancer Stage.
33. General Treatment Principles
Locally advanced disease has a greater risk of recurrence than low-grade organ-confined prostate cancer.
Principal Management Considerations
- Clinical T stage.
- PSA.
- Grade Group.
- Nodal status.
- Metastatic status.
- Age.
- Life expectancy.
- Comorbidities.
- Urinary function.
- Treatment preferences.
Main Treatment Options
- Radiotherapy with long-term ADT.
- Intensified radiotherapy-based treatment in eligible patients.
- Radical prostatectomy with pelvic lymph node dissection in selected patients.
- Postoperative radiation and/or systemic treatment when indicated.
- ADT alone when appropriate local treatment is not feasible.
34. Multimodal Treatment
Definition
Treatment using more than one therapeutic approach.
Important Examples
- Radiotherapy + ADT.
- Radiotherapy + ADT + abiraterone.
- Radical prostatectomy + pelvic lymph node dissection.
- Radical prostatectomy followed by salvage or selected adjuvant radiotherapy.
- Surgery followed by additional systemic treatment when indicated.
Clinical Importance
Combined Local And Systemic Treatment Is A Central Principle In Managing Fit Patients With Locally Advanced Prostate Cancer.
35. Androgen-Deprivation Therapy
ADT.
Mechanism
Reduces androgen stimulation of prostate cancer.
Main Methods
- GnRH agonists.
- GnRH antagonists.
- Bilateral orchiectomy.
36. GnRH Agonists
Examples
- Leuprolide.
- Goserelin.
- Triptorelin.
Mechanism
Continuous pituitary GnRH receptor stimulation eventually suppresses LH secretion and testicular testosterone production.
Important Adverse Effect
Initial testosterone flare.
37. GnRH Antagonists
Examples
- Degarelix.
- Relugolix.
Mechanism
Direct suppression of GnRH receptor signaling.
Main Advantage
Rapid testosterone reduction without initial androgen flare.
38. Surgical Orchiectomy
Definition
Bilateral surgical removal of testicular androgen-producing tissue.
Clinical Role
A permanent form of androgen deprivation.
Limitations
- Irreversibility.
- Sexual dysfunction.
- Psychological effects.
- Other consequences of long-term testosterone suppression.
39. ADT Monotherapy
Historical Source
The chapter describes ADT as an option for patients unwilling or unable to undergo surgery or radiation.
Contemporary Position
ADT alone is generally less effective than appropriate combined local and systemic treatment for fit patients with locally advanced nonmetastatic prostate cancer.
Current Selection Principle
ADT monotherapy may be considered when local treatment is not feasible, particularly in selected patients with aggressive or symptomatic disease.
Clinical Importance
ADT Monotherapy Should Not Automatically Replace Definitive Local Treatment In A Fit Patient With Potentially Curable Locally Advanced Prostate Cancer.
40. Antiandrogen Monotherapy
Historical Observation
The original source describes antiandrogen monotherapy as less effective but sometimes associated with better tolerability.
Contemporary Principle
First-generation antiandrogen monotherapy is generally not recommended as a preferred treatment strategy for locally advanced disease.
41. Radical Prostatectomy
RP.
Clinical Role
Potential curative treatment in selected patients with clinically node-negative locally advanced disease.
Important Considerations
- Patient fitness.
- Tumour resectability.
- MRI findings.
- Risk of positive margins.
- Probability of lymph node involvement.
- Expected urinary and sexual outcomes.
Clinical Importance
Radical Prostatectomy Can Be Considered For Selected cN0 Locally Advanced Prostate Cancers As Part Of A Planned Multimodal Strategy.
42. Clinical Overstaging
Historical Source
Clinical T3 overstaging was reported in approximately:
7–27% of Patients.
Clinical Importance
Some tumours classified as clinically T3 may prove less extensive on final pathology.
Important Principle
Clinical T3 Classification Alone Should Not Automatically Exclude Radical Prostatectomy In An Otherwise Suitable Patient.
43. Pelvic Lymph Node Dissection
Historical Recommendation
Radical prostatectomy with pelvic lymph node dissection.
Contemporary EAU Position
When lymph node dissection is performed:
Use an Extended Pelvic Lymph Node Dissection Template.
Clinical Purpose
- Determine pathological nodal status.
- Improve staging.
- Guide postoperative management.
Important Qualification
The therapeutic benefit of lymph node dissection itself remains less certain than its staging value.
44. Neoadjuvant ADT Before Surgery
Historical Source
Neoadjuvant ADT did not demonstrate a clear:
- Cancer-specific survival benefit.
- Overall survival benefit.
Contemporary Clinical Principle
Routine neoadjuvant ADT before radical prostatectomy is not established as standard treatment outside appropriate specialized or research settings.
45. Adjuvant Radiotherapy After Prostatectomy
Definition
Radiotherapy delivered following surgery before established biochemical recurrence.
Historical Source
The chapter recommends postoperative radiation for:
- T3 disease.
- Positive surgical margins.
- Gleason 8–10.
Historical Dose
55–70 Gy.
Historical Timing
Within approximately one year of surgery, following improvement or stabilization of postoperative urinary symptoms.
46. Contemporary Adjuvant Versus Early Salvage Radiation
Modern randomized trials have changed postoperative management.
Main Strategies
Adjuvant Radiotherapy
Treatment delivered despite undetectable postoperative PSA because of adverse pathology.
Early Salvage Radiotherapy
Treatment initiated when a postoperative PSA rise indicates likely residual or recurrent cancer.
Contemporary Clinical Importance
Early Salvage Radiotherapy Is Preferred Over Routine Adjuvant Radiation For Many Patients With Adverse Prostatectomy Pathology.
This approach avoids unnecessary radiation in patients who would otherwise remain recurrence-free.
47. Patients Who May Benefit From Adjuvant Radiation
Current EAU guidance supports offering adjuvant radiotherapy in selected patients with:
- pN0 disease.
- Pathological T3.
- ISUP Grade Group 4–5.
- With or without positive surgical margins.
Important Qualification
This is a selected high-risk group, not an automatic recommendation for every pT3 patient.
Clinical Importance
Very High-Risk Pathology May Justify Adjuvant Radiotherapy Despite The General Preference For Early Salvage Treatment In Many Patients.
48. Postoperative Node-Positive Disease
pN1.
Potential Management Options
- Adjuvant ADT.
- Adjuvant ADT with radiotherapy.
- Observation in carefully selected patients with limited nodal disease and undetectable PSA.
Clinical Importance
Postoperative node-positive disease requires individualized risk assessment.
49. External-Beam Radiotherapy
EBRT.
Historical Source
The chapter recommends definitive doses of approximately:
75–80 Gy
to appropriate target regions.
Historical Alternative
Approximately 40–50 Gy of EBRT combined with brachytherapy.
Important Qualification
Dose, fractionation, and treatment fields depend on contemporary radiation planning and are not universal fixed prescriptions.
50. Modern Radiation Techniques
Intensity-Modulated Radiotherapy
IMRT.
Volumetric Modulated Arc Therapy
VMAT.
Image-Guided Radiotherapy
IGRT.
Main Benefits
- More accurate target coverage.
- Improved dose conformity.
- Reduced unnecessary exposure to the rectum and bladder.
- Ability to deliver effective tumour doses.
Clinical Importance
Modern IMRT/VMAT With Image Guidance Is A Standard Technical Approach For Definitive Radiotherapy In Locally Advanced Prostate Cancer.
51. Radiotherapy With Long-Term ADT
Historical Recommendation
Approximately:
2–3 Years of ADT.
Contemporary EAU Recommendation
For cN0 locally advanced prostate cancer:
Radiotherapy Combined With At Least Two Years of ADT.
Clinical Importance
Long-Term ADT Combined With Radiotherapy Improves Cancer Outcomes Compared With Radiation Alone In Appropriate Locally Advanced Disease.
52. Brachytherapy Boost
Definition
Additional localized radiation delivered using radioactive sources within the prostate.
Main Types
- High-dose-rate brachytherapy.
- Low-dose-rate brachytherapy.
Current Role
May be offered in selected patients with:
- cN0 disease.
- Good urinary function.
- Appropriate prostate anatomy.
- Suitability for combined treatment.
Clinical Importance
Brachytherapy boost can improve local dose delivery but may increase urinary toxicity.
53. Treatment Intensification With Abiraterone
Drug
Abiraterone acetate.
Mechanism
Inhibits CYP17-dependent androgen synthesis.
Clinical Role
Additional systemic hormonal treatment for selected higher-risk nonmetastatic prostate cancer.
Important Requirement
Administered with an appropriate corticosteroid regimen and monitoring.
54. Abiraterone in cN0M0 Disease
Current EAU guidance recommends adding:
Two Years of Abiraterone
to definitive radiotherapy and long-term ADT for cN0M0 patients with at least two of the following:
- Clinical T3–T4.
- Gleason score 8 or higher.
- PSA at least 40 ng/mL.
Clinical Importance
Not Every cT3–T4 Patient Automatically Qualifies For Abiraterone; The Specified Additional High-Risk Criteria Must Be Met.
55. Abiraterone in cN1M0 Disease
Contemporary Recommendation
For suitable patients with regional lymph node involvement but no distant metastases:
- Prostate and pelvic radiotherapy.
- Long-term ADT.
- Two years of abiraterone.
Clinical Importance
Clinically Node-Positive Nonmetastatic Prostate Cancer Often Warrants Intensified Combined Local And Systemic Treatment.
56. STAMPEDE Evidence
Main Clinical Question
Does adding abiraterone to standard treatment improve outcomes in high-risk nonmetastatic prostate cancer?
Key Finding
The trial program demonstrated improved:
- Metastasis-free survival.
- Overall survival.
Reported Six-Year Metastasis-Free Survival
Abiraterone-based treatment: 82%.
Standard treatment: 69%.
Important Qualification
These were trial population estimates and do not represent the expected outcome of every individual patient.
57. Adverse Effects of Abiraterone
Important concerns include:
- Hypertension.
- Hypokalemia.
- Fluid retention.
- Abnormal liver function.
- Other cardiovascular or metabolic complications.
Clinical Monitoring
- Blood pressure.
- Serum potassium.
- Liver function.
- Clinical fluid status.
58. Cryotherapy
Historical Source
The chapter describes cryoablation as less effective than radiotherapy in a historical comparison involving T2c–T3 disease.
Reported Biochemical Failure
- Cryotherapy: 87%.
- Radiotherapy: 53%.
Important Qualification
These results represent a particular historical trial and should not be generalized to all contemporary techniques.
Contemporary Position
Cryotherapy Is Not Recommended As Routine Primary Treatment For Locally Advanced Prostate Cancer.
59. High-Intensity Focused Ultrasound
HIFU.
Mechanism
Produces local thermal tissue destruction through focused ultrasound.
Historical Source
Describes HIFU as investigational.
Contemporary Position
HIFU does not have an established role as routine primary treatment for locally advanced prostate cancer.
60. Focal Therapy
Principle
Targeted ablation of a selected tumour region.
Main Limitation
Locally advanced disease may extend beyond the treated area or contain occult multifocal tumour.
Clinical Importance
Focal Ablation Is Not An Established Substitute For Definitive Multimodal Treatment Of T3–T4 Prostate Cancer.
61. Clinical Trials
Patients with locally advanced disease may benefit from consideration of clinical trials evaluating:
- New treatment combinations.
- Treatment intensification.
- Molecular imaging-guided treatment.
- Novel hormonal therapy.
- Other emerging strategies.
62. Prognosis
General Principles
Prognosis depends on:
- Clinical stage.
- ISUP Grade Group.
- PSA.
- Tumour volume.
- Nodal involvement.
- Metastatic status.
- Treatment received.
- Overall health.
Clinical Importance
Untreated Locally Advanced Prostate Cancer Carries A Substantial Risk Of Progression And Disease-Specific Mortality.
63. Historical Outcomes Without Treatment
The source reports broad survival estimates.
Five-Year Overall Survival
10–92%.
Ten-Year Overall Survival
14–78%.
Important Qualification
These ranges reflect widely varying historical patient groups.
They are not reliable individualized survival predictions.
64. Historical Radical Prostatectomy Outcomes
Five-Year Overall Survival
64–96%.
Ten-Year Overall Survival
13–72%.
Five-Year Cancer-Specific Survival
85–92%.
Ten-Year Cancer-Specific Survival
79–82%.
Important Qualification
These are historical observational estimates affected by patient selection and treatment practices.
65. Historical Radiotherapy Outcomes
Radiotherapy Alone
Five-year overall survival:
60–70%.
Ten-year overall survival:
Below 50%.
Radiotherapy With ADT
Five-year overall survival:
72–87%.
Clinical Importance
These historical findings support the principle that combined radiation and hormonal treatment improves outcomes in suitable patients.
66. Prognostic Importance of PSA Doubling Time
Historical Adverse Threshold
Less Than 10 Months.
Associated Findings
The source identifies increased biochemical recurrence risk in patients with:
- Gleason score 8–10.
- Short PSA doubling time.
Clinical Importance
Rapid PSA Doubling After Treatment Raises Concern For Aggressive Recurrent Disease And Increased Risk Of Metastatic Progression.
67. Complications of Untreated Locally Advanced Disease
Hematuria
May develop from local tumour invasion or associated urinary tract pathology.
Bladder Outlet Obstruction
Tumour growth may impair urinary outflow.
Urinary Retention
May require catheter drainage.
Ureterovesical Junction Obstruction
Locally advanced tumour may obstruct one or both distal ureters.
Clinical Consequences
- Hydroureteronephrosis.
- Renal impairment.
- Recurrent urinary infection.
- Possible acute kidney injury.
68. Management of Urinary Obstruction
Bladder Outlet Obstruction
Possible measures include:
- Urethral catheterization.
- Suprapubic catheterization when indicated.
- Selected palliative transurethral resection.
Upper Urinary Tract Obstruction
Possible measures include:
- Ureteral stent.
- Percutaneous nephrostomy.
Clinical Importance
Obstruction-Related Renal Impairment May Require Urgent Drainage Independently Of The Definitive Prostate Cancer Treatment Plan.
69. Palliative Transurethral Resection
Channel TURP.
Clinical Role
May relieve severe bladder outlet obstruction in selected patients with advanced disease.
Important Qualification
This is intended for symptom relief rather than definitive oncological treatment.
70. Complications of Surgery
Potential complications include:
- Bleeding.
- Infection.
- Urinary incontinence.
- Erectile dysfunction.
- Anastomotic stricture.
- Lymphocele following pelvic lymph node dissection.
- Other operative complications.
Important Consideration
More extensive local tumour involvement may increase surgical complexity.
71. Complications of Radiation Therapy
Urinary Complications
- Dysuria.
- Frequency.
- Urgency.
- Hematuria.
- Radiation cystitis.
- Urethral stricture.
- Urinary incontinence.
Gastrointestinal Complications
- Radiation proctitis.
- Rectal bleeding.
- Diarrhea.
- Bowel urgency.
- Rare severe rectal injury.
Sexual Complications
- Erectile dysfunction.
- Reduced sexual function.
72. Complications of ADT
Important adverse effects include:
- Hot flushes.
- Fatigue.
- Loss of libido.
- Erectile dysfunction.
- Reduced muscle mass.
- Increased fat mass.
- Osteoporosis.
- Metabolic disturbances.
- Cardiovascular risk considerations.
Clinical Importance
Long-Term Hormonal Treatment Requires Bone, Metabolic, Cardiovascular, And Quality-of-Life Monitoring.
73. Follow-Up
Historical Source Schedule
PSA approximately:
Every Three Months Initially.
Intervals may gradually be extended toward annual follow-up in suitable stable patients.
Important Qualification
Monitoring frequency should reflect:
- Treatment received.
- PSA response.
- Recurrence risk.
- Ongoing ADT.
- Clinical symptoms.
74. PSA Monitoring After Radical Prostatectomy
Expected Result
PSA should generally become undetectable or extremely low.
Persistent PSA
May suggest residual local or systemic disease.
Rising PSA
May indicate biochemical recurrence.
Clinical Importance
An Unexpected Postoperative PSA Trend Requires Evaluation According To Pathological Risk And Available Salvage Treatment Options.
75. PSA Monitoring After Radiotherapy
PSA usually decreases gradually.
Important Features
- PSA nadir.
- Time to nadir.
- Subsequent PSA changes.
Standard Biochemical Recurrence Definition
PSA Nadir + 2 ng/mL.
Clinical Importance
PSA interpretation differs after prostatectomy and radiotherapy.
76. Evaluation of Suspected Recurrence
The historical source recommends additional imaging when PSA fails to reach an expected nadir or rises consecutively.
Historical Investigations
- Bone scintigraphy.
- CT.
- ProstaScint.
Contemporary Investigations
- PSMA PET/CT.
- Pelvic MRI.
- Other imaging according to clinical findings.
Clinical Importance
Imaging Should Be Selected When Its Findings Are Expected To Influence Salvage Or Systemic Treatment Decisions.
77. Management of Recurrence
Potential approaches include:
- Salvage radiotherapy.
- ADT.
- Other systemic treatment.
- Selected regional or metastasis-directed treatment.
- Clinical trial participation.
Important Qualification
The treatment depends on whether recurrence is:
- Local.
- Regional.
- Metastatic.
78. Clinical and Surgical Pearls
Definition and Staging
- cT3 indicates extraprostatic extension or seminal vesicle invasion.
- cT4 indicates fixation or invasion of adjacent structures.
- Clinical and pathological T stages may differ.
- Nodal and metastatic status must be assessed separately.
Risk Factors
- High PSA.
- High Gleason score.
- High Grade Group.
- Greater biopsy tumour volume.
- Advanced local tumour findings.
Diagnostic Evaluation
- DRE is important for clinical T staging.
- MRI assesses local extension.
- PSMA PET/CT improves metastatic staging.
- Biopsy establishes histology and Grade Group.
- No single investigation perfectly predicts pathological tumour extent.
Treatment
- Radiotherapy With Long-Term ADT Is A Major Standard Treatment For cN0 Locally Advanced Disease.
- Radical prostatectomy may be offered to selected cN0 patients.
- Extended pelvic lymph node dissection is recommended when dissection is performed.
- Two years of abiraterone is recommended for eligible very-high-risk or cN1M0 patients.
- Routine primary cryotherapy and HIFU are not recommended.
Postoperative Treatment
- Adjuvant radiotherapy is not mandatory for every pT3 patient.
- Early salvage radiotherapy is appropriate for many patients with PSA recurrence.
- Selected high-grade pT3 patients may benefit from adjuvant treatment.
79. Essential Examination Principles
1. Know the T3 Subclassification
T3a indicates extraprostatic extension, and T3b indicates seminal vesicle invasion.
2. Know the T4 Definition
Tumour fixation or invasion of adjacent structures beyond the seminal vesicles.
3. Understand the Importance of MRI
It helps determine local disease extent but cannot exclude every instance of microscopic extension.
4. Use PSMA PET/CT for Staging When Available
It is particularly valuable in high-risk and locally advanced cancer.
5. Recognize the Need for Multimodal Treatment
Combined local and systemic treatment is frequently necessary.
6. Remember the Standard cN0 Treatment
Radiotherapy with long-term ADT.
7. Know the ADT Duration
At least two years for appropriate locally advanced disease treated with radiation.
8. Know the Abiraterone Eligibility Criteria
For cN0M0, at least two of cT3–T4, Gleason score 8 or higher, and PSA at least 40 ng/mL.
9. Recognize cN1M0 Treatment Intensification
Prostate and pelvic radiotherapy with long-term ADT and two years of abiraterone in eligible patients.
10. Remember Surgery Is Still Possible
Selected cN0 patients may undergo radical prostatectomy as part of a multimodal plan.
11. Perform Appropriate Nodal Dissection
An extended template is recommended when pelvic lymph node dissection is performed.
12. Distinguish Adjuvant From Early Salvage Radiation
Routine adjuvant radiation is not necessary for all adverse pathological findings.
13. Avoid Routine Primary Cryotherapy or HIFU
They are not established treatments for locally advanced disease.
14. Recognize Urinary Complications
Locally advanced cancer may produce bladder outlet and distal ureteral obstruction.
15. Continue Long-Term PSA Surveillance
Post-treatment PSA kinetics help detect recurrence and determine further treatment.
80. Historical Clinical Context and Important Qualifications
Historical Incidence
The original source describes declining clinical presentation of locally advanced disease during the early PSA era.
These percentages are not current incidence estimates.
Historical PSA Predictive Values
The reported PSA positive predictive values apply to specific clinical populations and should not be used as universal staging probabilities.
PSA Density and PSA Velocity
The source describes specific numerical thresholds for cancer detection or extraprostatic extension.
Contemporary assessment combines biomarkers, Grade Group, MRI, and other validated predictors.
MRI
The source describes MRI as an adjunct with selected staging accuracy estimates.
Contemporary multiparametric MRI has a major role in local staging and treatment planning.
PSMA PET/CT
Not included in the historical source.
It is now a preferred staging investigation for high-risk and locally advanced disease when available.
Surgery for cT3 Disease
The source emphasizes the possibility of clinical overstaging.
This remains relevant: carefully selected patients should not automatically be excluded from surgery.
Adjuvant Radiotherapy
The historical chapter recommends adjuvant treatment broadly for T3 disease and positive surgical margins.
Contemporary randomized evidence supports early salvage radiation for many patients, while selected very-high-risk pathological groups remain candidates for immediate treatment.
Abiraterone
The original chapter predates STAMPEDE evidence supporting two years of abiraterone in selected high-risk nonmetastatic patients.
ADT Monotherapy
The source presents ADT as an option for patients unsuitable for other treatments.
Current practice emphasizes that eligible patients achieve better outcomes with appropriately combined local and systemic therapy.
Cryotherapy and HIFU
The historical source describes these as experimental or less effective approaches.
Current EAU guidance does not recommend them as primary treatment for locally advanced prostate cancer.
Historical Survival Estimates
The survival percentages should not be interpreted as modern individualized prognosis.
They reflect heterogeneous cohorts with substantial differences in tumour risk, selection, and treatment.
81. Historical Diagnostic Codes
ICD-9
185
Malignant neoplasm of prostate.
198.1
Secondary malignant neoplasm of other urinary organs.
198.82
Secondary malignant neoplasm of genital organs.
ICD-10 Codes Listed in the Source
C61
Malignant neoplasm of prostate.
C79.11
Secondary malignant neoplasm of bladder.
C79.82
Secondary malignant neoplasm of genital organs.
Important Coding Qualification
These codes are preserved from the historical source.
Direct contiguous invasion of neighboring structures by primary prostate cancer is not necessarily equivalent to a separate secondary metastatic malignancy at that site. Current coding must reflect the documented disease and applicable coding rules.
Final Urological Revision Summary
Locally advanced prostate cancer consists of clinically T3 or T4 prostate malignancy, characterized by extension beyond the prostate or invasion of neighboring structures.
Main Staging Features
T3a
Extraprostatic extension.
T3b
Seminal vesicle invasion.
T4
Fixation or invasion of adjacent structures beyond the seminal vesicles.
Major Risk Factors
- High PSA.
- High Grade Group.
- Extensive biopsy involvement.
- Greater tumour volume.
- Adverse local examination findings.
Main Diagnostic Priorities
- Clinical examination and DRE.
- PSA assessment.
- Prostate MRI.
- Prostate biopsy.
- ISUP grading.
- PSMA PET/CT when available.
- Evaluation of regional lymph nodes.
- Exclusion of distant metastatic disease.
- Assessment of urinary function and fitness for treatment.
Contemporary Treatment Approach
cT3–T4 N0 M0
- Definitive radiotherapy with long-term ADT.
- Radical prostatectomy with appropriate nodal assessment in selected patients.
- Selected brachytherapy boost.
- Additional abiraterone when specified high-risk criteria are met.
cN1 M0
- Prostate and pelvic radiotherapy.
- Long-term ADT.
- Two years of abiraterone in eligible patients.
After Radical Prostatectomy
- Close PSA monitoring.
- Early salvage radiotherapy when indicated.
- Selected adjuvant radiotherapy for particularly high-risk pathology.
- Additional systemic treatment according to nodal status and recurrence risk.
Patients Unable to Receive Definitive Local Treatment
- Individualized hormonal or palliative management.
Main Complications
- Bladder outlet obstruction.
- Urinary retention.
- Hematuria.
- Distal ureteral obstruction.
- Hydronephrosis.
- Renal impairment.
- Urinary incontinence.
- Erectile dysfunction.
- Radiation cystitis.
- Radiation proctitis.
- ADT-related metabolic and skeletal complications.
Main Prognostic Factors
- PSA.
- Clinical stage.
- ISUP Grade Group.
- Seminal vesicle invasion.
- Nodal involvement.
- PSA response and doubling time.
- Overall patient health.
- Treatment intensity and effectiveness.
Follow-Up Priorities
- Serial PSA.
- Testosterone assessment during ADT when appropriate.
- Urinary symptom evaluation.
- Renal function when obstruction is present.
- Monitoring of treatment toxicities.
- Imaging when recurrence or progression is suspected.
- Long-term multidisciplinary surveillance.
The Central Urological Objective Is To Accurately Stage T3–T4 Prostate Cancer, Identify Regional And Distant Spread, Select Appropriate Multimodal Therapy, Optimize Cancer Control, Prevent Urinary Tract Complications, And Preserve Quality Of Life Through Careful Long-Term Follow-Up.